A US Study to Look at Loss of Work and Healthcare Costs for People Affected With Mild-to-moderate COVID 19 Who Have High Chances of the Disease Becoming Severe

Study at a glance

From the registry record, last updated by the sponsor on 9 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title

Work Productivity Losses in the United States Among High-risk Patients With COVID-19 During Acute and Longer-term Follow-up in an Omicron Predominant Period (PULSE-US)

ClinicalTrials.gov ID

NCT07072793

Acronym / sponsor ID

C4671066

Conditions

COVID-19 (Coronavirus Disease 2019)

Keywords

SARS Coronavirus, SARS Virus, SARS-CoV, SARS-CoV-1, Paxlovid, omicron

Study type

Observational

Recruitment status

Completed

Enrolment

131,005 participants (actual)

Lead sponsor

PfizerIndustry (pharma, biotech, devices)

Study start

31 Oct 2024 (actual)

Primary completion

15 Nov 2024 (actual)

Study completion

15 Nov 2024 (actual)

First posted

18 Jul 2025 (actual)

Results

Posted 12 Jan 2026

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Observational model

Other

Time perspective

Retrospective

Number of arms

2

Who may qualify

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Age groups

Adult, Older adult

Study population

retrospective cohort study of adult, high-risk patients diagnosed with COVID-19 using data from the Merative™ MarketScan® Commercial, Medicare, and Health and Productivity Management (HPM) Databases. The index date for both cohorts will be the date of the first COVID-19 diagnosis and patients will be followed over a 6-month pre-period and variable post-period. The post-period will be a minimum of 30 days to allow patients the opportunity to experience the primary study outcomes of work loss days (absence, STD, and LTD) along with associated indirect costs.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Primary outcome

1. Number of Participants According to Age Group: Unmatched Participants

   Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

   Age group was categorized into following categories: 18-29 years, 30-39 years, 40-49 years, 50-64 years and 65-74 years. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

2. Number of Participants According to Age Group: Matched Participants

   Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

   Age group was categorized into following categories: 18-29 years, 30-39 years, 40-49 years, 50-64 years and 65-74 years. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

3. Number of Participants According to Sex: Unmatched Participants

   Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

   Sex was categorized as: female and male. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

4. Number of Participants According to Sex: Matched Participants

   Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

   Sex was categorized as: female and male. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

5. Number of Participants According to Region of Residence: Unmatched Participants

   Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

   Region of residence was categorized into following categories: Northeast, North Central, South, West, and other/ missing. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

6. Number of Participants According to Region of Residence: Matched Participants

   Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

   Region of residence was categorized into following categories: Northeast, North Central, South, West and other/ missing. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

7. Number of Participants According to Payer Type: Unmatched Participants

   Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

   Payer type was categorized as: commercial and medicare. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

8. Number of Participants According to Payer Type: Matched Participants

   Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

   Payer type was categorized as: commercial and medicare. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

9. Number of Participants According to Insurance Plan Type: Unmatched Participants

   Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

   Insurance plan type was categorized into following categories: comprehensive/indemnity, exclusive/preferred provider organization (EPO/PPO), point of service capitation (POS) with or without capitation, health maintenance organization (HMO), consumer driven/ high-deductible health plan (CDHP/HDHP) and missing/unknown. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

10. Number of Participants According to Insurance Plan Type: Matched Participants

    Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

    Insurance plan type was categorized into following categories: comprehensive/indemnity, EPO/PPO, POS with or without capitation, HMO, CDHP/HDHP and missing/unknown. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

11. Number of Participants According to Industry Type: Unmatched Participants

    Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

    Industry type was categorized into following categories: finance/insurance/real estate, manufacturing (durable/non-durable goods), retail trade, services, transportation/communications/utilities and other. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

12. Number of Participants According to Industry Type: Matched Participants

    Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

    Industry type was categorized into following categories: finance/insurance/real estate, manufacturing (durable/non-durable goods), retail trade, services, transportation/communications/utilities and other. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

13. Number of Participants According to Quarter (Q) of Index Year: Unmatched Participants

    Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

    Quarter of index year was categorized into following categories: Q4 2021, Q1 2022, Q2 2022, Q3 2022 and Q4 2022. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

14. Number of Participants According to Quarter of Index Year: Matched Participants

    Time frame: At index date (any date during index date identification period of approximately 11.5 months); retrospective data collected was evaluated in 0.5 months of this study

    Quarter of index year was categorized into following categories: Q4 2021, Q1 2022, Q2 2022, Q3 2022 and Q4 2022. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

15. Mean Duration of Follow-up: Unmatched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Duration of follow-up was defined as number of months from (and including) the index date to the end of participants variable-length follow-up period. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

16. Mean Duration of Follow-up: Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Duration of follow-up was defined as number of months from (and including) the index date to the end of participants variable-length follow-up period. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

17. Mean Elixhauser Comorbidity Index (ECI): Unmatched Participants

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    ECI was a measure of comorbidity based on ICD-10 codes. ECI score range was from 0-30. A higher score indicated more comorbidity. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

18. Mean ECI: Matched Participants

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    ECI was a measure of comorbidity based on ICD-10 codes. ECI score range was from 0-30. A higher score indicated more comorbidity. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

19. Mean Charlson Comorbidity Index (CCI): Unmatched Participants

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    CCI based on various comorbid conditions such as cerebrovascular disease, chronic pulmonary disease, congestive heart failure, dementia, mild/moderate diabetes, diabetes with chronic complications, hemiplegia/paraplegia, human immunodeficiency virus(HIV), mild liver disease, moderate/severe liver disease, malignancy, metastatic solid tumor, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease, rheumatologic disease was reported. CCI score range was from 0 to 33, where "0"= low comorbid condition and "33"= high comorbid condition, higher scores indicated more comorbidity. Index date was the date of first COVID-19 diagnosis. Data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

20. Mean CCI: Matched Participants

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    CCI based on various comorbid conditions such as cerebrovascular disease, chronic pulmonary disease, congestive heart failure, dementia, mild/moderate diabetes, diabetes with chronic complications, hemiplegia/paraplegia, HIV, mild liver disease, moderate/severe liver disease, malignancy, metastatic solid tumor, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease, rheumatologic disease was reported. CCI score range was from 0 to 33, where "0"= low comorbid condition and "33"= high comorbid condition, higher scores indicated more comorbidity. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

21. Number of Participants According to Comorbidities: Unmatched Participants

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Comorbidities were categorized into following categories: cancer (current or history of), cardio/cerebrovascular disease, chronic kidney disease, chronic liver disease, diabetes mellitus, immunocompromised status, lung disease or tuberculosis, neurodevelopmental disorder/complex condition, overweight/obesity or smoking and pregnancy. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. Participant can have more than 1 comorbidity.

22. Number of Participants According to Comorbidities: Matched Participants

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Comorbidities were categorized into following categories: cancer (current or history of), cardio/cerebrovascular disease, chronic kidney disease, chronic liver disease, diabetes mellitus, immunocompromised status, lung disease or tuberculosis, neurodevelopmental disorder/complex condition, overweight/obesity or smoking and pregnancy. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category. Participant can have more than 1 comorbidity.

23. Number of High-risk Conditions Per Participant: Unmatched Participants

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    High risk conditions included cancer, cerebrovascular or peripheral vascular disease, chronic lung disease, chronic liver disease, cystic fibrosis, dementia, diabetes, disability, heart conditions, HIV, hypertension, immunocompromised state(primary immunodeficiencies, prolonged use of corticosteroids or other immunosuppressive medications, and other immunocompromised state), mental health conditions(mood disorder or schizophrenia), overweight or obesity, physical inactivity, pregnancy(current or recent), sickle cell disease or thalassemia, smoking (current or former), solid organ or blood stem cell transplant, substance use disorder, tuberculosis. Index date=date of first COVID-19 diagnosis. Data was reported for unmatched participants, they were further sub-grouped on basis of outcome of COVID-19: eligible for absence from work, short term disability, long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

24. Number of High-risk Conditions Per Participant: Matched Participants

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    High risk conditions included cancer, cerebrovascular or peripheral vascular disease, chronic lung disease, chronic liver disease, cystic fibrosis, dementia, diabetes, disability, heart conditions, HIV, hypertension, immunocompromised state (primary immunodeficiencies, prolonged use of corticosteroids or other immunosuppressive medications, and other immunocompromised state), mental health conditions (mood disorder or schizophrenia), overweight or obesity, physical inactivity, pregnancy(current or recent), sickle cell disease or thalassemia, smoking (current or former), solid organ or blood stem cell transplant, substance use disorder, tuberculosis. Index date=date of first COVID-19 diagnosis. Data was reported for matched participants, they were further sub-grouped on basis of outcome of COVID-19: eligible for absence from work, short term disability, long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

25. Number of Participants According to COVID-19 Vaccination Status: Unmatched Participant

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Number of participants with >=1 claim for a COVID-19 vaccination during the pre-period was reported in this outcome measure. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

26. Number of Participants According to COVID-19 Vaccination Status: Matched Participant

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Number of participants with >=1 claim for a COVID-19 vaccination during the pre-period was reported in this outcome measure. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

27. Number of Participants With One or More Prior Hospitalization: Unmatched Participants

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Prior hospitalization indicated participants who had one or more inpatients visits in the pre-period. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

28. Number of Participants With One or More Prior Hospitalization: Matched Participants

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Prior hospitalization indicated participants who had one or more inpatients visits in the pre-period. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

29. Number of Participants With One or More Prior Emergency Room (ER) Visit: Unmatched Participants

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Prior ER visit indicates participants who had one or more ER visits in pre-period. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for unmatched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

30. Number of Participants With One or More Prior Emergency Room (ER) Visit: Matched Participants

    Time frame: Pre-period (6 months period before index date; during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Prior ER visit indicates participants who had one or more ER visits in pre-period. Index date was the date of first COVID-19 diagnosis. In this outcome measure, data was reported for matched participants, they were further sub-grouped on the basis of outcome of COVID-19: eligible for absence from work, eligible for short term disability and eligible for long term disability. These sub-groups were not mutually exclusive; some participants might be represented in more than one category.

31. Number of Participants With Presence of Any Absence Records: Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Number of participants with presence of any absence records was reported in this outcome measure. Index date was the date of first COVID-19 diagnosis.

32. Mean Number of Absence Days Per Participant Per Month (PPPM): Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    In this outcome measure mean number of absence days PPPM was reported. Index date was the date of first COVID-19 diagnosis.

33. Number of Participants According to Type for Absence Claim: Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Absence days was reported by absence type: sick, disability and recreational absence. Sick, disability and recreational absence were the leaves which participants took during the study period. Sick absence referred to the time away from work due to an employee's own illness or medical condition, this may be also used for bereavement, caring for a family member with a serious health condition, adoption-related medical needs. Disability absence was recorded when an employee was unable to work due to a short-term or long-term disability. Recreational absence referred to the time off taken for non-medical, personal reasons, such as vacation, personal leave, leisure, or wellness days. Index date was the date of first COVID-19 diagnosis. One participant may have more than one type of absence claim.

34. Mean Cost of Absence Days: Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Estimated sum of wages associated with absence days was calculated as daily wage multiplied by absence days was reported PPPM in this outcome measure. Index date was the date of first COVID-19 diagnosis.

35. Number of Participants With Any Short Term Disability (STD) Claim: Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Number of participants with presence of any STD claim was reported in this outcome measure. Index date was the date of first COVID-19 diagnosis.

36. Mean Number of STD Days PPPM: Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    In this outcome measure mean number of STD days PPPM was reported. Index date was the date of first COVID-19 diagnosis.

37. Number of Participants According to Reason for STD Claim: Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Reasons for STD were classified as COVID-19 related or non-COVID-19 related or missing/unknown. Index date was the date of first COVID-19 diagnosis.

38. Mean Cost of STD Days: Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Estimated sum of wages associated with absence days STD claim was calculated as 70 percentage (%) of daily wage multiplied by STD days was reported PPPM in this outcome measure. Index date was the date of first COVID-19 diagnosis.

39. Number of Participants With Any Long Term Disability (LTD) Claim: Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Number of participants with presence of any LTD claim was reported in this outcome measure. Index date was the date of first COVID-19 diagnosis.

40. Mean Number of LTD Days PPPM: Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    In this outcome measure mean number of LTD days PPPM was reported. Index date was the date of first COVID-19 diagnosis.

41. Number of Participants According to Reason for LTD Claim: Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Reasons for LTD were classified as COVID-19 related or non-COVID-19 related or missing/unknown. Index date was the date of first COVID-19 diagnosis.

42. Mean Cost of LTD Days: Matched Participants

    Time frame: From index date to the end of follow-up (maximum follow-up was up to an average of 8.3 months during data observation of approximately 1.5 years); retrospective data collected was evaluated in 0.5 months of this study

    Estimated sum of wages associated with absence days LTD claim was calculated as 70 percent (%) of daily wage multiplied by LTD days was reported PPPM in this outcome measure. Index date was the date of first COVID-19 diagnosis.

Results and safety

Loading the posted results from ClinicalTrials.gov…

Research links

• Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2026.
• Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
• To obtain contact information for a study center near you, click here.Link provided by the sponsor.
• Individual participant dataSharing planned: No. Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Related trials for COVID-19 (Coronavirus Disease 2019)

• Not yet recruitingPhase 1

  Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

  Post-Acute COVID-19 Syndrome

• Active, not recruitingPhase 1

  A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults

  COVID-19

• Active, not recruiting

  Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers

  Mental Health Issue, Mental Health Disorder

• Recruiting

  Home-Based Exercise Tele-Rehabilitation After COVID-19

  Post SARS-CoV2 (COVID-19)

• Not yet recruitingPhase 1

  A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine

  COVID -19

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

1 site in 1 country: see every site and its status.